AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06334159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane
Description: Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
Study NCT06334159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane
Description: Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
Study NCT03018197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Education
Description: Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
Study NCT02508584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-mycoplasma hominis antibodies
Description: provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
Study NCT01562392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: berries and vegetables
Description: Daily (5 w) supplementation with specific vegetables and berries
Study NCT01562392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control product
Description: Supplementation (daily,5 w) with a control product without berries and vegetables.
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol
Description: 50g erythritol dissolved in 300mL tap water
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol + lactisole
Description: 50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose
Description: 25g D-allulose dissolved in 300mL tap water
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose + lactisole
Description: 25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water
Description: 300mL tap water
Study NCT04027283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Tap water + lactisole
Description: 300mL tap water + lactisole (450ppm)
Study NCT02355652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total knee replacement using cemented components
Description: Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
Study NCT02355652 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total knee replacement using uncemented components
Description: Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
Study NCT01960712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transpapillary plastic stent (7-10 Fr)
Description: Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
Study NCT03167463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flap
Description: Repair choanal atresia with using flap during surgery
Study NCT04067453 — intervention group
Intervention type: OTHER
Intervention: Fatiguing contractions
Description: 10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
Study NCT04026386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center Based or In Home Early Intervention Program
Description: This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment or in home to treat social communication deficits in children with developmental disorders.
Study NCT04547842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine 30 MG
Description: mirtazapine is given in arm M to prevent PONV
Study NCT02771054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF/FTC
Description: Change of nucleoside backbone
Study NCT03585998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Concurrent radiotherapy Maintenance therapy
Study NCT03129984 — intervention group
Intervention type: DEVICE
Intervention: Mandibular movement tracking
Description: Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
Study NCT02345603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryo-therapy
Description: Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
Study NCT04004325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101
Description: FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
Study NCT04004325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-4101 placebo
Description: FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
Study NCT04004325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated Water
Description: Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
Study NCT01280513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein intake
Description: 30% of energy intake coming from proteins
Study NCT04547842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is given in arm D to prevent PONV
Study NCT01476332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-urocanic acid 0,5% eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study NCT01280513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein intake
Description: 9% of energy intake coming from proteins
Study NCT02696161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
Study NCT02696161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose
Description: Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
Study NCT01237067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
Study NCT01237067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
Study NCT02394028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: Etrolizumab will be administered as per regimen specified in individual arms.
Study NCT01644994 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intracavitary cisplatin-fibrin
Description: single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
Study NCT00984048 — intervention group
Intervention type: OTHER
Intervention: Needle core biopsies of liver metastasis
Description: No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
Study NCT01476332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-urocanic acid 2.5% eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study NCT01476332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for cis-UCA, eye drops
Description: one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
Study NCT02572245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PF-06410293 PFS
Description: PF-06410293 40 mg administered subcutaneously by Prefilled syringe
Study NCT02572245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PF-06410293 PFP
Description: PF-06410293 40 mg administered subcutaneously by prefilled pen
Study NCT04688060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Falls Efficacy Scale-International (FES-I)
Description: The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
Study NCT05757440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Icon resin application
Description: Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
Study NCT02748421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumera Microscope with OCT RESCAN
Description: macular membrane dissection with OCT RESCAN
Study NCT02748421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Microscope
Description: macular membrane dissection without OCT RESCAN
Study NCT03550443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules
Study NCT03550443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing an inert placebo
Study NCT00425698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant erythropoietin alpha (rHuEPO alpha)
Description: Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Study NCT00425698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Study NCT00425698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
Study NCT01835977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation (Nanoknife)
Study NCT03668496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Study NCT03668496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The placebo
Description: in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Study NCT01684696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual experience
Study NCT01684696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videos
Study NCT01157338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnostic cardiac catheterization
Description: coronary intervention: angiography
Study NCT01157338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic cardiac catheterization
Description: cardiac catheterization: angioplasty
Study NCT04057924 — intervention group
Intervention type: OTHER
Intervention: abstention from CIN2 treatment and surveillance for at least 2 years
Description: Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
Study NCT02626429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid intake
Description: Amino acid intakes will be varied at 0.2-2.6 g/kg/day
Study NCT00916201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URB597
Description: 10 mg / d for 5 days, orally
Study NCT00916201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal Insulin
Description: 160 IU / d for 5 days, intranasal
Study NCT00916201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol CR
Description: 320 mg / d for 5 days, orally
Study NCT02546258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A Fungal Nail Treatment
Description: treats the signs of mild fungal nail infections
Study NCT03877315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
Description: A total shoulder prosthesis used in treating glenohumeral osteoarthritis
Study NCT03877315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
Description: A total shoulder prosthesis used in treating glenohumeral osteoarthritis
Study NCT03492957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
Study NCT03660865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Description: Primary eye will receive Light adjustable lens with Light delivery Device treatments
Study NCT03660865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control IOL
Description: Fellow eye will receive control IOL
Study NCT02250508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study NCT02250508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemate P® (Human Coagulation Factor VIII)
Study NCT03985943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03985943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab
Study NCT01597765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcuminoids, N-acetylcysteine, deferiprone and vitamin E
Description: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
Study NCT01597765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoids and alpha-tocopherol
Description: group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
Study NCT02459431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 21 G needle group
Description: Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
Study NCT02459431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 22 G needle group
Description: Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
Study NCT02029755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversus abdominis plane block
Description: bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
Study NCT02029755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
Study NCT02029755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: postoperative analgesia with intravenous patient controlled analgesia with morphine
Study NCT02029755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia
Description: postoperative analgesia with intravenous patient controlled analgesia with morphine
Study NCT02766439 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: 25-mg etanercept injection subcutaneously twice a week
Study NCT00453037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: structured educational program
Description: structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
Study NCT00453037 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: participation in the educational program after 6 months
Description: Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
Study NCT04610619 — intervention group
Intervention type: OTHER
Intervention: Immunological challenge
Description: In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
Study NCT01555853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study NCT02888691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Study NCT02888691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Study NCT04082845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Web-based patient education
Study NCT04534179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum myofascial therapy and physical activity program.
Description: This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program
Study NCT02394028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
Study NCT02394028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
Study NCT01646255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period
Study NCT01646255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches
Study NCT01646255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-dopa
Description: Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
Study NCT01646255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.